Hypothalamic Obesity Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Rhythm Pharmaceuticals, and others

Hypothalamic Obesity emerging therapies such as LB54640, and others are expected to boost the Hypothalamic Obesity Market in the upcoming years.

DelveInsight has launched a new report on "Hypothalamic Obesity - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed sample report @ https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the Hypothalamic Obesity Market:
In March 2025, Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to setmelanotide for the treatment of hypothalamic obesity. This designation is intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies for serious or life-threatening conditions.
In March 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to setmelanotide for treating acquired hypothalamic obesity. This status is given to drugs addressing rare diseases, facilitating their development and approval processes.

Some of the key facts of the Hypothalamic Obesity Market Report:

Hypothalamic obesity is a complex disorder often caused by hypothalamic damage due to brain tumors, surgery, radiation therapy, head trauma, or genetic abnormalities.
Research indicates that the estimated yearly incidence of tumor- or treatment-related hypothalamic obesity (TTR-HO) in Germany ranges from 0.7 to 1.7 cases per million people.
Common symptoms of hypothalamic obesity include excessive hunger, an inability to feel full, rapid weight gain, daytime drowsiness, disrupted circadian rhythms, and imbalances in thirst regulation, body temperature, heart rate, and blood pressure, among others.
Traditional treatment approaches include a calorie-restricted diet, exercise therapy, and pharmacological interventions, but no fully effective treatment currently exists. Pharmacotherapy primarily targets alterations in efferent pathways, with commonly used off-label treatments including sympathomimetic appetite suppressants, leptin-sensitizing drugs, hormone replacement therapy, stimulants, and GLP-1 agonists.
Recent advancements in understanding the condition have led to promising developments in treatment. In January 2024, Rhythm Pharmaceuticals announced the completion of patient screening for a pivotal Phase III clinical trial evaluating setmelanotide in individuals with acquired hypothalamic obesity. The company has closed enrollment and expects to exceed its initial target, with more than 140 patients undergoing active screening and baseline assessments.
Additionally, in the same month, Rhythm Pharmaceuticals entered a global licensing agreement with LG Chem for LB54640, an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist currently in Phase II clinical trials. This partnership highlights the growing pharmaceutical efforts to develop treatments for hypothalamic obesity.
Despite these advancements, there remains an urgent need for further clinical research and development to address the increasing prevalence of hypothalamic obesity effectively.
Key Hypothalamic Obesity companies such as Rhythm Pharmaceuticals, and others are evaluating new drugs for Hypothalamic Obesity to improve the treatment landscape.
Promising Hypothalamic Obesity pipeline therapies in various stages of development include LB54640, IMCIVREE, and others.
Key benefits of the Hypothalamic Obesity market report:
Hypothalamic Obesity market report covers a descriptive overview and comprehensive insight of the Hypothalamic Obesity Epidemiology and Hypothalamic Obesity market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Hypothalamic Obesity market report provides insights on the current and emerging therapies.
Hypothalamic Obesity market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Hypothalamic Obesity market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hypothalamic Obesity market.

Got queries? Click here to know more about the Hypothalamic Obesity Market Landscape https://www.delveinsight.com/sample-request/hypothalamic-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hypothalamic Obesity Overview

Hypothalamic obesity is a rare disorder resulting from damage to the hypothalamus, the brain region responsible for controlling hunger and metabolism. This damage, which can be caused by tumors like craniopharyngiomas, brain injuries, or surgical procedures, disrupts appetite regulation and energy balance, leading to uncontrollable weight gain. Individuals with hypothalamic obesity often struggle with rapid weight gain, decreased energy expenditure, and resistance to conventional weight-loss strategies.

To know more about hypothalamic obesity, treatment options, visit: https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hypothalamic Obesity Market Outlook

Leading companies, including LG Chem and Rhythm Pharmaceuticals, are advancing their drug candidates through various stages of clinical development to explore potential treatments for hypothalamic obesity.

This segment provides a comprehensive analysis of the hypothalamic obesity market, assessing each approved drug and late-stage pipeline therapy. It evaluates their impact based on factors such as annual treatment costs, inclusion and exclusion criteria, mechanism of action, patient compliance rates, market demand, growing patient population, target patient demographics, anticipated launch timelines, competition with existing therapies, brand positioning, market influence, and insights from key opinion leaders.

Discover how the hypothalamic obesity market is rising in the upcoming years, click: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hypothalamic Obesity Emerging Drugs
IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
LB54640 (LR19021): LG Chem/ Rhythm Pharmaceuticals

Scope of the Hypothalamic Obesity Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypothalamic Obesity Companies: Rhythm Pharmaceuticals, and others
Key Hypothalamic Obesity Therapies: IMCIVREE, LB54640, and others
Hypothalamic Obesity Therapeutic Assessment: Hypothalamic Obesity current marketed and Hypothalamic Obesity emerging therapies
Hypothalamic Obesity Market Dynamics: Hypothalamic Obesity market drivers and Hypothalamic Obesity market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Hypothalamic Obesity Unmet Needs, KOL's views, Analyst's views, Hypothalamic Obesity Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hypothalamic Obesity Patient Share (%) Overview at a Glance
5. Hypothalamic Obesity Market Overview at a Glance
6. Hypothalamic Obesity Disease Background and Overview
7. Hypothalamic Obesity Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypothalamic Obesity
9. Hypothalamic Obesity Current Treatment and Medical Practices
10. Unmet Needs
11. Hypothalamic Obesity Emerging Therapies
12. Hypothalamic Obesity Market Outlook
13. Country-Wise Hypothalamic Obesity Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hypothalamic Obesity Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Hypothalamic Obesity Market Outlook 2034 https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Hypothalamic Obesity Pipeline Insights, DelveInsight

"Hypothalamic Obesity Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hypothalamic Obesity market. A detailed picture of the Hypothalamic Obesity pipeline landscape is provided, which includes the disease overview and Hypothalamic Obesity treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.